Compare UHAL & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHAL | EXAS |
|---|---|---|
| Founded | 1945 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.0B |
| IPO Year | N/A | N/A |
| Metric | UHAL | EXAS |
|---|---|---|
| Price | $53.04 | $101.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $76.38 |
| AVG Volume (30 Days) | 181.1K | ★ 9.7M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $5,972,459,000.00 | $3,082,033,000.00 |
| Revenue This Year | $3.18 | $16.68 |
| Revenue Next Year | $3.71 | $12.36 |
| P/E Ratio | $44.35 | ★ N/A |
| Revenue Growth | 5.86 | ★ 14.47 |
| 52 Week Low | $48.48 | $38.81 |
| 52 Week High | $75.19 | $101.87 |
| Indicator | UHAL | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 90.46 |
| Support Level | $48.48 | $101.01 |
| Resistance Level | $53.14 | $101.61 |
| Average True Range (ATR) | 1.24 | 2.75 |
| MACD | 0.40 | 2.44 |
| Stochastic Oscillator | 86.99 | 98.11 |
U-Haul Holding Co is an American moving truck, trailer, and self-storage rental company. The company also provides moving boxes, packing supplies, LPG (propane) refills, trailer hitch and wiring installation, storage container rentals, and other services. It has three reportable segments Moving and Storage, Property and Casualty Insurance, and Life Insurance. The majority of its revenue comes from the Moving and Storage segment.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.